SPHERIC-1OE (Sildenafil and Pulmonary HypERtension In COPD – Open Extension) - A multicenter, longitudinal, 12 months open-label study, for the observation of the use of sildenafil in the treatment of patients with pulmonary hypertension associated to chronic obstructive lung disease enrolled in SPHERIC-1 study
Latest Information Update: 21 Oct 2015
At a glance
- Drugs Sildenafil (Primary)
- Indications Pulmonary hypertension
- Focus Adverse reactions
- Acronyms SPHERIC-1 OPEN EXTENSION
- 17 Oct 2015 Status changed from recruiting to completed as reported by European Clinical Trials Database.
- 09 Mar 2014 New trial record